Montelukast is widely used in patients with asthma. Several preclinical data suggest that it
could be repositioned as novel strategy for managing rheumatic patients by decreasing
inflammatory mediators.
Considering the probable enhanced antiarthritic effects of montelukast; it could be
hypothesized that its adjuvant use might improve treatment outcomes in rheumatic patients who
remain poorly controlled despite initial optimal guidelines directed medical treatment.
Therefore, this study aims to evaluate the potential added benefits of montelukast use in
conjunction with csDMARDs in RA patients with moderate and high disease activity.